CG Oncology rises as traders price in near-term Phase 3 PIVOT-006 data and target hikes
CGON•CG Oncology shares are higher as investors position ahead of multiple first-half 2026 clinical readouts for its lead bladder-cancer candidate, cretostimogene, including Phase 3 PIVOT-006 topline data. Recent analyst price-target hikes into the $75–$100 range have also supported momentum in the stock.
1) What’s moving the stock today
CG Oncology (CGON) is moving higher as the market continues to trade the company around an approaching catalyst window in the first half of 2026, when the company expects to report topline data from its Phase 3 PIVOT-006 trial evaluating cretostimogene as an adjuvant therapy in intermediate-risk non-muscle invasive bladder cancer. With the next major readout nearing, biotech traders often bid up shares on “catalyst anticipation,” especially when the program is central to the company’s thesis. (globenewswire.com)
